From the Journals

E. coli resistant to colistin and carbapenems found in U.S. patient


 

The first strain of Escherichia coli harboring the antibiotic-resistant genes mcr-1 and blaNDM-5 was isolated in the urine of a U.S. patient, according to a report in mBio.

A 76-year-old man was admitted to a tertiary-care hospital in New Jersey with a fever and flank pain in August 2014. The patient emigrated from India and resided in the United States for 1 year prior to this presentation. He had a history of prostate cancer treated with radiation therapy and subsequently developed recurrent urinary tract infections. He had also experienced bladder perforation requiring bilateral placement of nephrostomy tubes, which were clamped 5 days prior to presentation.

E. coli Manjurul/Thinkstock

An E. coli culture in the laboratory.

A clean catch urine culture collected from the patient grew greater than 100,000 CFU/ml of Pseudomonas aeruginosa, Citrobacter koseri, and Enterococcus faecium. Similarly, a urine culture collected from the patient’s nephrostomy tube grew more than 100,000 CFU/ml of P. aeruginosa, E. coli, Klebsiella pneumoniae, Enterococcus spp., and methicillin-resistant Staphylococcus aureus. Susceptibility testing results also showed that the E. coli isolate was resistant to colistin and all beta-lactam antimicrobials (including carbapenems) except aztreonam, but was susceptible to amikacin, gentamicin, nitrofurantoin, tigecycline, and trimethoprim-sulfamethoxazole.

Using molecular analysis, the E. coli isolate from the study case (named MCR1_NJ) was shown to carry both mcr-1 and blaNDM-5 genes. In addition to mcr-1 and blaNDM-5, strain MCR1_NJ was found to harbor resistance genes for aminoglycosides, beta-lactams, chloramphenicol, fluoroquinolones, rifampin, sulfonamides, and tetracycline.

“This strain was isolated in August 2014, highlighting an earlier presence of mcr-1 within the region than previously known and raising the likelihood of ongoing undetected transmission,” wrote José R. Mediavilla, MBS, MPH of the New Jersey Medical School, Rutgers University, Newark, N.J., and his coauthors. “Active surveillance efforts involving all polymyxin- and carbapenem-resistant organisms are imperative in order to determine mcr-1 prevalence and prevent further dissemination.”

Find the full study in mBio (doi: 10.1128/mBio.01191-16).

Recommended Reading

Many patients with diabetic foot infections get unnecessary MRSA treatment
MDedge Infectious Disease
New drugs poised to stem tide of antibacterial resistance in gonorrhea
MDedge Infectious Disease
Checklist may prompt cuts in unneeded antibiotic prescriptions
MDedge Infectious Disease
Update on the third international consensus definitions for sepsis and septic shock
MDedge Infectious Disease
Gonorrhea cluster shows increased antibiotic resistance
MDedge Infectious Disease
MRSA patients report signs of stigma tied to illness
MDedge Infectious Disease
Hospital managers identify barriers to antimicrobial stewardship
MDedge Infectious Disease
FDA to streamline development of antimicrobials, susceptibility test devices
MDedge Infectious Disease
Ceftazidime-avibactam stands up to CRE, but resistance a problem
MDedge Infectious Disease
Striking the balance: Who should be screened for CP-CRE acquisition?
MDedge Infectious Disease